Remed Co.Ltd (302550) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Remed Co.Ltd (302550) has a cash flow conversion efficiency ratio of 0.006x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩238.69 Million ≈ $161.76K USD) by net assets (₩39.24 Billion ≈ $26.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 302550 company net worth for the company's overall valuation and market capitalisation.
Remed Co.Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Remed Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Remed Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Remed Co.Ltd ranked by their cash flow conversion efficiency. Explore 302550 cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Man Zai Industrial Co Ltd
TWO:4543
|
0.047x |
|
Hotelim Société Anonyme
PA:MLHOT
|
N/A |
|
Pangaea Oncology S.A.
MC:PANG
|
-0.057x |
|
Inter Industries
TA:ININ
|
0.229x |
|
Covalon Technologies Ltd.
V:COV
|
0.218x |
|
META WOLF AG INH O.N.
F:WOLF
|
N/A |
|
Patria Latin American Opportunity
NASDAQ:PLAO
|
-0.009x |
|
TLGY Acquisition Corp
NASDAQ:TLGY
|
0.026x |
Annual Cash Flow Conversion Efficiency for Remed Co.Ltd (2017–2025)
The table below shows the annual cash flow conversion efficiency of Remed Co.Ltd from 2017 to 2025. View 302550 stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩39.46 Billion ≈ $26.74 Million |
₩2.40 Billion ≈ $1.62 Million |
0.061x | +96.37% |
| 2024-12-31 | ₩40.25 Billion ≈ $27.28 Million |
₩1.24 Billion ≈ $843.40K |
0.031x | -72.79% |
| 2023-12-31 | ₩30.79 Billion ≈ $20.87 Million |
₩3.50 Billion ≈ $2.37 Million |
0.114x | -34.77% |
| 2022-12-31 | ₩29.92 Billion ≈ $20.28 Million |
₩5.21 Billion ≈ $3.53 Million |
0.174x | +230.28% |
| 2021-12-31 | ₩26.10 Billion ≈ $17.69 Million |
₩-3.49 Billion ≈ $-2.36 Million |
-0.134x | -227.93% |
| 2020-12-31 | ₩24.79 Billion ≈ $16.80 Million |
₩2.59 Billion ≈ $1.76 Million |
0.105x | -20.14% |
| 2019-12-31 | ₩24.62 Billion ≈ $16.69 Million |
₩3.22 Billion ≈ $2.18 Million |
0.131x | +550.48% |
| 2018-12-31 | ₩10.94 Billion ≈ $7.42 Million |
₩-317.96 Million ≈ $-215.48K |
-0.029x | -282.16% |
| 2017-12-31 | ₩4.19 Billion ≈ $2.84 Million |
₩66.75 Million ≈ $45.24K |
0.016x | -- |
About Remed Co.Ltd
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells,… Read more